Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
Condition(s):Endometrial CancerLast Updated:November 3, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Endometrial CancerLast Updated:November 3, 2023Terminated
Condition(s):Endometrial Atypical Hyperplasia; Endometrial AdenocarcinomaLast Updated:September 14, 2021Completed
Condition(s):Tumor; Chemotherapy-induced Nausea and VomitingLast Updated:June 12, 2020Unknown status
Condition(s):AnorexiaLast Updated:May 18, 2022Recruiting
Condition(s):Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial CarcinomaLast Updated:March 12, 2024Recruiting
Condition(s):Atypical Endometrial HyperplasiaLast Updated:June 18, 2020Completed
Condition(s):Atypical Endometrial Hyperplasia; Endometrial CarcinomaLast Updated:January 5, 2024Active, not recruiting
Condition(s):Atypical Endometrial HyperplasiaLast Updated:April 5, 2022Terminated
Condition(s):FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; Metastatic Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Cancer AJCC v8Last Updated:March 28, 2024Recruiting
Condition(s):Breast CancerLast Updated:January 30, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.